NEW
YORK, Sept. 30, 2022 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of Kiromic BioPharma, Inc.
(NASDAQ: KRBP).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/kiromic-biopharma-inc-loss-submission-form/?id=32221&from=4
This lawsuit is on behalf of a class consisting of persons and
entities that purchased or otherwise acquired: (a) Kiromic common
stock issued in connection with the Company's public offering that
closed on July 2, 2021 and/or (b)
Kiromic common stock between June 25,
2021 and August 13, 2021, both
dates inclusive.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
October 4, 2022 to petition
the court. Your ability to share in any recovery doesn't require
that you serve as a lead plaintiff.
The complaint alleges that the registration statement and
prospectus issued in connection with the Company's public offering
that closed on July 2, 2021 (the
"Offering Documents") failed to disclose that the Food and Drug
Administration ("FDA") had, prior to the filing of these
documents, imposed a clinical hold on the Company's Investigational
New Drug ("IND") applications for its two new drug candidates.
Given that the offering closed on July 2,
2021, more than thirty (30) days after the Company submitted
the IND applications for its two immunotherapy product candidates,
investors were assured that no clinical hold had been issued and
clinical trials would commence.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/krbp-shareholder-alert-jakubowitz-law-reminds-kiromic-shareholders-of-a-lead-plaintiff-deadline-of-october-4-2022-301637301.html
SOURCE Jakubowitz Law